## 1 Brief Report

# 2 3

# Phosphatidylethanolamines are the main lipid class altered in red blood cells from patients with VPS13A disease/chorea-acanthocytosis

- 4 Kevin Peikert, MD<sup>1,2,3</sup>, Adrian Spranger<sup>1</sup>, Gabriel Miltenberger-Miltenyi, MD<sup>4</sup>, Hannes Glaß,
- 5 PhD<sup>1</sup>, Björn Falkenburger, MD<sup>5,6</sup>, Christian Klose, PhD<sup>7</sup>, Donatienne Tyteca, PhD<sup>8</sup>, Andreas
- 6 Hermann, MD PhD<sup>1,2,3,9</sup>
- 7 <sup>1</sup>Translational Neurodegeneration Section "Albrecht Kossel", Department of Neurology, University Medical Center Rostock,
- 8 University of Rostock, Germany
- 9 <sup>2</sup> Center for Transdisciplinary Neurosciences Rostock (CTNR), University Medical Center Rostock, Rostock, Germany
- 10 <sup>3</sup> United Neuroscience Campus Lund-Rostock (UNC), Rostock site
- 11 <sup>4</sup> Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Portugal
- 12 <sup>5</sup> Department of Neurology, Technische Universität Dresden, Dresden, Germany
- 13 <sup>6</sup> Deutsches Zentrum für Neurodegenerative Erkrankungen, Dresden, Germany
- 14 <sup>7</sup> Lipotype GmbH, Dresden, Germany
- 15 <sup>8</sup> CELL Unit, de Duve Institute, UCLouvain, Brussels, Belgium
- 16 <sup>9</sup> Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) Rostock/Greifswald, Rostock, Germany
- 17

# 18 **Corresponding Author:**

- 19 Prof. Andreas Hermann, MD, PhD; Translational Neurodegeneration Section "Albrecht
- 20 Kossel"; Department of Neurology; University Medical Center Rostock; Gehlsheimer Straße
- 21 20, 18147 Rostock, Germany; Phone: +49(0)381 494-9511; e-Mail:
- 22 Andreas.Hermann@med.uni-rostock.de
- 23
- 24 Running Title: Lipidomics in VPS13A disease
- 25 Word count (up to 1700 words, abstract 150): 1707, 151
- 26 Figures/tables (up to 2): 2
- 27 **References (up to 40):** 26
- 28 Financial Disclosure/Conflict of Interests: CK is CTO and shareholder of Lipotype GmbH,
- 29 other than that none related to the manuscript.
- 30 Funding Sources: This study was funded by the MeDDrive grant (TU Dresden). K.P. is
- supported by Rostock Academy of Science (RAS). A.H. is supported by the Hermann und Lilly
- 32 Schilling-Stiftung für medizinische Forschung im Stifterverband.
- 33
- 34
- 35
- 36
- 37

## 38 Abstract

39 Background: VPS13A disease (chorea-acanthocytosis) is an ultra-rare disorder caused by loss 40 of function mutations in VPS13A characterized by striatal degeneration and by red blood cell 41 (RBC) acanthocytosis. VPS13A is a bridge-like protein mediating bulk lipid transfer at 42 membrane contact sites. 43 **Objectives:** To assess the lipid composition of patient-derived RBCs. 44 Methods: RBCs collected from 5 VPS13A disease patients and 12 control subjects were analyzed by mass spectrometry (lipidomics). 45 **Results:** While we found no significant differences on the overall lipid class level, alterations 46 47 in certain species were detected: phosphatidylethanolamine species with both longer chain length and higher unsaturation were increased in VPS13A disease samples. Specific 48 49 ceramide, phosphatidylcholine and sphingomyelin species were also altered. 50

50 **Conclusions:** The presented alterations of particular lipid species in RBCs in VPS13A disease 51 contribute to 1) the understanding of acanthocyte formation and 2) future biomarker 52 identification. Lipid distribution seems to play a key role in the pathophysiology of VPS13A 53 disease.

- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- ---
- 64

# 65 Introduction

VPS13A disease (formerly known as chorea-acanthocytosis) is a neurodegenerative disorder 66 of the young adulthood and an important differential of Huntington's disease<sup>1</sup>. Together 67 with XK disease (McLeod syndrome) it has been classified as neuroacanthocytosis syndrome 68 as it is characterized by striatal degeneration and the presence of deformed red blood cells 69 (RBCs), referred to as acanthocytes<sup>2</sup>. Typical clinical manifestations include a variety of 70 movement disorders (chorea and dystonia with orofacial predominance, in later stages 71 72 parkinsonism), epilepsy, behavioral and cognitive impairment as well as peripheral neuroand myopathy<sup>1</sup>. 73

The autosomal-recessive condition is caused by biallelic pathogenic variants in the VPS13A 74 gene leading in most cases to a complete loss of the respective protein, VPS13A/chorein<sup>3</sup>. 75 VPS13A belongs to a family of 4 proteins, VPS13A-D, that are all related to 76 neurodegenerative or neurodevelopmental disorders, such as hereditary parkinsonism 77 (VPS13C) or ataxia (VPS13D)<sup>4-6</sup>. Only recently, VPS13A has been assigned to the new protein 78 superfamily of bridge-like lipid transfer proteins (BLTPs)<sup>7,8</sup>. Forming hydrophobic grooves 79 that span between two organellar membranes at membrane contact sites, these proteins 80 mediate direct bulk lipid transfer, most likely selective for phospholipids<sup>9</sup>. VPS13A localizes 81 between the endoplasmic reticulum and mitochondria, lipid droplets or the plasma 82 membrane<sup>9</sup>. At the plasma membrane, it has been shown to form a complex with the 83 putative scramblase XK<sup>10,11</sup>. In support of a pathomechanistic role of altered membrane lipid 84 distribution and supply in VPS13A disease, elevated levels of several sphingo- and 85 phospholipids have been recently found in the striatum of VPS13 patients<sup>12</sup>. Also, in 86 Huntington's disease, a distinct shift in the sphingolipid profile of the caudate has been 87 reported<sup>13</sup>. 88

In this exploratory study, we aimed to study the lipid composition of RBCs from VPS13A patients for various reasons: 1) RBCs are – besides neurons – prominently affected by the disease as a high proportion are acanthocytic. 2) RBCs are "products" of a complex rearrangement of membranes and organelles during erythropoiesis<sup>14</sup> potentially requiring membrane lipid transfer. 3) RBCs are – in contrast to brain tissue – easily obtainable. RBC lipid composition may therefore be an ideal biomarker candidate.

95

96

## 97 Methods

Five genetically confirmed VPS13 patients (4 males, 1 female, mean age 45.6, min 32, max 52
years) and 12 healthy controls (9 males, 3 females, mean age 40.7, min 23, max 56 years)
were included in this study. Demographic and clinical data of patients are shown in Table S1.
The study was approved by the ethics committee at the Technische Universität Dresden
(EK45022009, EK78022015). All participants gave written informed consent in accordance
with the Declaration of Helsinki.

EDTA blood samples were processed in accordance to the sample preparation guidelines from Lipotype GmbH (Dresden, Germany; see supplementary material). Mass spectrometrybased lipid analysis was performed by Lipotype GmbH as previously described using a QExactive Orbitrap mass spectrometer (Thermo Fisher Scientific, Darmstadt, Germany)<sup>15</sup>. Table S2 shows the list of analyzed lipid classes and the respective structural detail level of the analysis.

Lipid data was analyzed in mol% for better comparability. An occupational threshold was applied to filter lipid (sub)species that were not adequately measured to solidify findings (see supplementary material).

113 Multiple t-tests on all remaining (sub)species were performed (without assuming a 114 consistent standard deviation). In order to account for multiple testing, the Benjamini 115 Hochberg procedure with a false discovery rate of 5% was used. Analysis was performed at 116 different levels: lipid class level, lipid (sub)species level, structural or functional category 117 level as well as grouped by chain length/double bounds number/OH-groups number. For 118 visualization of the results on the lipid (sub)species level, a Vulcano plot was generated.

119

### 120 **Results**

121 There was no statistically significant difference in age and sex distribution between the two 122 groups analyzed in this study (Table S3).

123 Untargeted lipidomic analysis was achieved by mass spectrometry by screening for 23 lipid classes. In total, 575 lipid species and subspecies were measured. After application of the 124 occupational threshold, 313 lipid species and subspecies remained for further analysis. Out 125 of the 23 classes, 13 were easily detectable including ceramide (Cer), cholesterol (Chol), 126 127 hexosylceramide (HexCer), lyso-phosphatidylcholine (LPC), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylcholine-ether (PE O-), phosphatidylinositol (PI), 128 phosphatidylserine (PS) and sphingomyelin (SM), in agreement with previous reports on 129 RBCs <sup>16</sup>. Moreover, we were able to detect additional species such as lyso-130 131 phosphatidylethanolamine (LPE), phosphatidate (PA) and phosphatidylcholine-ether (PC O-).

On the lipid class level, no relevant differences between healthy controls and VPS13A 132 133 patients could be detected (Fig 1A). The most distinct difference was seen in the PI class with less mol% in the disease group, however, this did not reach statistical significance (p=0.07, 134 135 q=0.51). Also, after grouping the lipids into structural (glycerophospholipids, sphingolipids, and sterols) or functional categories (lyso vs. membrane lipids), analysis did not reveal 136 137 striking differences (Fig 1 B, C), as was the case for the number of double bounds and hydroxyl groups of the lipids (Fig 1 D, E). Likewise, while there was a tendency of decrease of 138 139 lipids with medium length fatty acid chains (30-36 C-atoms) and of increase of lipids with very long chains (39-44 C-atoms) in the patient group compared to control, none of these 140 differences reached statistical significance (Fig 1 F). 141

142 On the lipid species and subspecies level, however, distinct differences with small effect size 143 (fold change) were observed. The increase of Cer34:1;2 was the most significant finding (Fig 144 2 A, B). Most of the (sub)species with significant change after Benjamini Hochberg procedure 145 belonged to the PE or PE O- classes. Within the PEs, a shift in the fatty chain lengths became obvious: PE subspecies with longer fatty acid chains tended to be increased, species with 146 147 shorter chains to be decreased (Fig. 2 C). This is in line with the (nonsignificant) shift that has been observed in the overall chain length analysis (Fig. 1 F). In addition, decrease of single PC 148 149 and SM species were also detected.

150

# 151 **Discussion**

VPS13A disease has recently become paradigmatic for a new pathophysiological concept in neurodegeneration: disturbed bulk lipid transfer at membrane contact sites<sup>2,9,17</sup>. VPS13A is a bridge-like protein enabling direct bulk lipid transfer between intracellular membranes. It seems that disturbances of this process are central for VPS13A and related diseases although the exact role of bulk lipid transfer in neuronal and other mainly affected cells such as RBCs is subject of further research.

158 Based on these recent molecular developments in the field, we studied for the first time the lipid composition of RBCs from VPS13A patients using state-of-the-art lipidomics analysis. 159 160 RBCs are clearly affected by the disease as acanthocytosis is a core feature and VPS13A deficient RBCs reflect at least partly the pathophysiology of the disease<sup>1,18-20</sup>. Therefore, 161 162 RBCs may be an easily accessible surrogate and biomarker for pathology of the nervous system. Of note, there is significant evidence that lipid dysmetabolism is causal for the 163 development of acanthocytosis. First, hypo-/abetalipoproteinemia leads to the appearance 164 of acanthocytes <sup>21,22</sup>. Second, in liver failure where acanthocytosis is observed, irregularities 165 in lipid metabolism, particularly an excess of chol, have been associated with the 166 deformation of RBCs<sup>23</sup>. On the other side, lipid analysis in the "pre-lipidomics era" has not 167 revealed consistent differences in RBCs from neuroacanthocytosis patients<sup>18</sup>. 168

In line with that, our study did not show a generalized major disturbance of lipid classes, but
revealed interesting distinct changes at the lipid species and subspecies level, including PE
(O-) and Cer, but also single PC, and SM (sub)species.

172 PE play a central role in autophagosome formation and is a regulator of autophagy<sup>24</sup>, a process which has been shown to be impaired in VPS13A disease, as reflected by the 173 presence of membrane remnants<sup>19,20</sup>, and which is essential during erythropoiesis. 174 Moreover, the relative abundance of PE species highly evolves during reticulocyte 175 176 maturation into RBCs: longer and more unsaturated PE species decrease whereas smaller saturated ΡE al, 177 and more species increase (Minetti et BioRxiv, https://doi.org/10.1101/2023.06.02.543386). Interestingly, we showed here a reverse "acyl 178 chain remodeling": The former group increased in VPS13A patients while the latter 179 180 decreased, suggesting impairment of RBC maturation. Therefore, these findings may be related to acanthocyte formation during erythropoiesis and the pathophysiology of VPS13A 181 182 disease. Supporting this possibility, Cer, PC and PE species were also shown to be affected in

hypobetalipoproteinemia, another acanthocyte-related disease<sup>22</sup>. Interestingly, Csf1, a
 Vps13-like BLTP, has been shown to transfer PEs to the ER for GPI anchor synthesis<sup>25</sup>.

Also, as PE is a non-bilayer forming lipid, especially with longer chain length<sup>26</sup>, an increase of longer PE species might at least partially explain the morphological alterations of acanthocytes. Moreover, non-bilayer lipids may affect integration of proteins into membranes, their lateral movement and their function<sup>27</sup>.

189 Cer act as the foundational element for complex sphingolipids and is important in cellular 190 signaling. Accordingly, abnormal Cer levels have been associated with several 191 neurodegenerative conditions<sup>28</sup>.

192 The rather distinct lipid alterations may be viewed as unexpected considering the function of 193 VPS13A as lipid transfer protein. However, as most of the altered lipids are phospholipids, this finding is consistent with the suspected role of VPS13A as (specifically) phospholipid 194 transferring protein<sup>9</sup>. Also, quantitative analyses might not have captured localized changes 195 196 in membrane composition without major disturbances of overall lipid content. Furthermore, 197 variations within the RBC population (e.g., acanthocytic vs. non-acanthocytic) could have masked specific alterations in a subgroup of cells. As VPS13A plays a role in lipid transfer 198 199 between organellar membranes and as mature RBCs lack such organelles, the pathogenic 200 process occurs potentially mainly during erythropoiesis. Therefore, guantitative lipid analysis 201 might reveal more pronounced alterations in RBC precursor cells. Another limitation of this 202 study relates to the low number of patient samples due to the ultra-rarity of the disease 203 which might have resulted in an insufficient statistical power to detect even more sub2tle 204 changes.

The RBC lipidomics data presented are not conclusive with the data derived from post mortem brain tissue<sup>12</sup>. This is partially due to the differences in covered lipid classed by the measurements. However, this may also point to different effects of VPS13A deficiency in RBCs and the brain.

In summary, the alterations of particular lipid species in RBCs in VPS13A disease contributes
to the pathophysiological understanding. Further studies need to focus on lipid composition
of RBC precursor cells and on potential localized changes in distinct RBC membrane domains.

Also, our results may result in the development of PE species as biologically relevant biomarker for VPS13A disease which is a prerequisite for future clinical studies<sup>29</sup>.

214

#### 215 Acknowledgments

We thank the patients and control subjects for participating in this study. We are grateful to Glenn (†) and Ginger Irvine as the founders of the Advocacy for Neuroacanthocytosis Patients (www.naadvocacy.org) and to Susan Wagner and Joy Willard-Williford as representatives of the NA Advocacy USA (www.naadvocacyusa.org). We thank the advocacies for their support and research funding. We also thank Dr. Jenny Leopold (Institute for Medical Physics and Biophysics, Faculty of Medicine, Leipzig University, Germany) for her expert advice.

K.P. is supported by the Rostock Academy of Science (RAS), A.H. by the "Hermann und Lilly SchillingStiftung für medizinische Forschung im Stifterverband". D.T. is Senior Research Associate of Belgian
F.R.S.-FNRS.

225

#### 226 Authors' Roles

- 227 KP, HG, AH study design. KP and AH: patient recruitment, KP, AS, HG execution. KP, AS, GMM, BF,
- 228 CK, DT data analysis. KP, AH: funding acquisition. AH: supervision, project administration; KP, AS,

229 GMM, DT – writing. All authors - editing of final version of the manuscript.

230

#### 231 Financial Disclosures of all authors (for the preceding 12 months)

232 KP: Received funding from the Rostock Academy of Science (RAS) and the Deutschen Gesellschaft für

233 Parkinson und Bewegungsstörungen e.V. Stock Ownership in medically-related fields.

AH has received personal fees and non-financial support from ITF Pharma, Biogen and Desitin during

the conduct of the study outside of the submitted work. He received funding from the Schilling

- 236 Stiftung für medizinische Forschung im Stifterverband, VDI/BMBF, ESF, target ALS foundation outside
- the submitted work.
- 238 CK is CTO and shareholder of Lipotype GmbH.
- AS, GMM, HG, BF, DT have no financial disclosure to declare.



# 246 Figures





Fig 1 Lipidomics analysis on lipid class (A), structural category (B), functional category (C) level.
Structural analysis of lipids in respect to number of double bounds (D), fatty acid chain length (E), and
number of hydroxyl groups (F).

*Ctrl* controls, *VPS13A* VPS13A patients, *Cer* Ceramide, *Chol* Cholesterol, *HexCer* Hexosylceramide, *LPC*lyso-Phosphatidylcholine, *LPE* lyso-Phosphatidylethanolamine, *PA* Phosphatidate, *PC* (*O*-)
Phosphatidylcholine (-ether), *PE* (*O*-) Phosphatidylethanolamine (-ether), *PI* Phosphatidylinositol, *PS*Phosphatidylserine, *SM* Sphingomyelin, *GPL* glycerophospholipids, *SL* sphingolipids, *ST* sterols, *LYS*lyso lipids, *MEM* membrane lipids.

#### 257 Figure 2



258

Fig 2 Lipidomics analysis on species and subspecies level. Volcano blot showing all analysed (sub)species (A). The horizonal dotted line represents the threshold of statistical significance after Benjamini Hochberg procedure with a false discovery rate of 5%. (B) shows all significantly different (sub)species between healthy control and VPS13A disease groups. (C) Relative change of Phosphatidylethanolamine (PE) subspecies in VPS13A disease sorted by fatty acid chain length and double bond number; results are expressed as percentage of controls (healthy control values were set 100%).

*Ctrl* controls, *VPS13A* VPS13A patients, *Cer* Ceramide, *Chol* Cholesterol, *HexCer* Hexosylceramide, *LPC*lyso-Phosphatidylcholine, *LPE* lyso-Phosphatidylethanolamine, *PA* Phosphatidate, *PC* (*O*-)
Phosphatidylcholine (-ether), *PE* (*O*-) Phosphatidylethanolamine (-ether), *PI* Phosphatidylinositol, *PS*Phosphatidylserine, *SM* Sphingomyelin

270		
210		

- 271
- 272
- 273
- 274
- 275
- 276
- 277

# 278 **References**

- Peikert K, Dobson-Stone C, Rampoldi L, et al. VPS13A Disease. *GeneReviews® [Internet]*.
   University of Washington, Seattle; 1993; 2002 [updated 2023].
- 281 2. Walker RH, Peikert K, Jung HH, Hermann A, Danek A. Neuroacanthocytosis Syndromes: The
- 282 Clinical Perspective. Contact (Thousand Oaks). 2023;6:25152564231210339.
- 283 doi:10.1177/25152564231210339

Dobson-Stone C, Velayos-Baeza A, Filippone LA, et al. Chorein detection for the diagnosis of
 chorea-acanthocytosis. *Ann Neurol*. Aug 2004;56(2):299-302. doi:10.1002/ana.20200

286 4. Velayos-Baeza A, Vettori A, Copley RR, Dobson-Stone C, Monaco AP. Analysis of the human

287 VPS13 gene family. *Genomics*. Sep 2004;84(3):536-49. doi:10.1016/j.ygeno.2004.04.012

288 5. Lesage S, Drouet V, Majounie E, et al. Loss of VPS13C Function in Autosomal-Recessive

289 Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy.

290 Am J Hum Genet. Mar 3 2016;98(3):500-513. doi:10.1016/j.ajhg.2016.01.014

291 6. Seong E, Insolera R, Dulovic M, et al. Mutations in VPS13D lead to a new recessive ataxia with

- spasticity and mitochondrial defects. Ann Neurol. Jun 2018;83(6):1075-1088. doi:10.1002/ana.25220
- 293 7. Braschi B, Bruford EA, Cavanagh AT, Neuman SD, Bashirullah A. The bridge-like lipid transfer

294 protein (BLTP) gene group: introducing new nomenclature based on structural homology indicating

295 shared function. *Hum Genomics*. Dec 02 2022;16(1):66. doi:10.1186/s40246-022-00439-3

296	8.	Kumar N, Leonzino M, Hancock-Cerutti W, et al. VPS13A and VPS13C are lipid transport
297	protein	s differentially localized at ER contact sites. J Cell Biol. Oct 1 2018;217(10):3625-3639.
298	doi:10.:	1083/jcb.201807019
299	9.	Hanna M, Guillén-Samander A, De Camilli P. RBG Motif Bridge-Like Lipid Transport Proteins:

300 Structure, Functions, and Open Questions. Annu Rev Cell Dev Biol. Jul 05 2023;doi:10.1146/annurev-

301 cellbio-120420-014634

302 10. Park JS, Neiman AM. XK is a partner for VPS13A: a molecular link between Chorea303 Acanthocytosis and McLeod Syndrome. *Mol Biol Cell*. 10 2020;31(22):2425-2436.
304 doi:10.1091/mbc.E19-08-0439-T

Guillén-Samander A, Wu Y, Pineda SS, et al. A partnership between the lipid scramblase XK
and the lipid transfer protein VPS13A at the plasma membrane. *Proc Natl Acad Sci U S A*. Aug 30
2022;119(35):e2205425119. doi:10.1073/pnas.2205425119

Miltenberger-Miltenyi G, Jones A, Tetlow AM, et al. Sphingolipid and Phospholipid Levels Are
Altered in Human Brain in Chorea-Acanthocytosis. *Mov Disord*. Aug 2023;38(8):1535-1541.
doi:10.1002/mds.29445

311 13. Phillips GR, Saville JT, Hancock SE, et al. The long and the short of Huntington's disease: how

312 the sphingolipid profile is shifted in the caudate of advanced clinical cases. Brain Commun.

313 2022;4(1):fcab303. doi:10.1093/braincomms/fcab303

Moras M, Lefevre SD, Ostuni MA. From Erythroblasts to Mature Red Blood Cells: Organelle
Clearance in Mammals. *Frontiers in physiology*. 2017;8:1076. doi:10.3389/fphys.2017.01076

316 15. Sampaio JL, Gerl MJ, Klose C, et al. Membrane lipidome of an epithelial cell line. *Proc Natl* 

317 *Acad Sci U S A*. Feb 01 2011;108(5):1903-7. doi:10.1073/pnas.1019267108

318 16. Leidl K, Liebisch G, Richter D, Schmitz G. Mass spectrometric analysis of lipid species of

319 human circulating blood cells. Biochim Biophys Acta. Oct 2008;1781(10):655-64.

320 doi:10.1016/j.bbalip.2008.07.008

321 17. Peikert K, Danek A. VPS13 Forum Proceedings: XK, XK-Related and VPS13 Proteins in

- 322 Membrane Lipid Dynamics. Contact2023.
- 323 18. Adjobo-Hermans MJ, Cluitmans JC, Bosman GJ. Neuroacanthocytosis: Observations, Theories
- and Perspectives on the Origin and Significance of Acanthocytes. *Tremor Other Hyperkinet Mov (N Y)*.
- 325 2015;5:328. doi:10.7916/D8VH5N2M
- 326 19. Lupo F, Tibaldi E, Matte A, et al. A new molecular link between defective autophagy and
- 327 erythroid abnormalities in chorea-acanthocytosis. Blood. Dec 22 2016;128(25):2976-2987.
- 328 doi:10.1182/blood-2016-07-727321
- 329 20. Peikert K, Federti E, Matte A, et al. Therapeutic targeting of Lyn kinase to treat chorea-
- acanthocytosis. Acta Neuropathol Commun. May 2021;9(1):81. doi:10.1186/s40478-021-01181-y
- 331 21. Levy E. Insights from human congenital disorders of intestinal lipid metabolism. J Lipid Res.
- 332 May 2015;56(5):945-62. doi:10.1194/jlr.R052415
- 22. Cloos AS, Daenen LGM, Maja M, et al. Impaired Cytoskeletal and Membrane Biophysical
- 334 Properties of Acanthocytes in Hypobetalipoproteinemia A Case Study. Frontiers in physiology.
- 335 2021;12:638027. doi:10.3389/fphys.2021.638027
- 336 23. Sharma R, Holman CJ, Brown KE. A thorny matter: Spur cell anemia. *Ann Hepatol.* 337 2023;28(1):100771. doi:10.1016/j.aohep.2022.100771
- 338 24. Hsu P, Shi Y. Regulation of autophagy by mitochondrial phospholipids in health and diseases.
- 339 Biochim Biophys Acta Mol Cell Biol Lipids. Jan 2017;1862(1):114-129.
- 340 doi:10.1016/j.bbalip.2016.08.003
- 341 25. Toulmay A, Whittle FB, Yang J, et al. Vps13-like proteins provide phosphatidylethanolamine
- for GPI anchor synthesis in the ER. J Cell Biol. Mar 07 2022;221(3)doi:10.1083/jcb.202111095
- 343 26. de Kruijff B. Lipid polymorphism and biomembrane function. Curr Opin Chem Biol. Dec
- 344 1997;1(4):564-9. doi:10.1016/s1367-5931(97)80053-1

345 27. van den Brink-van der Laan E, Killian JA, de Kruijff B. Nonbilayer lipids affect peripheral and

- 346 integral membrane proteins via changes in the lateral pressure profile. *Biochim Biophys Acta*. Nov 03
- 347 2004;1666(1-2):275-88. doi:10.1016/j.bbamem.2004.06.010
- 348 28. Clausmeyer L, Fröhlich F. Mechanisms of Nonvesicular Ceramide Transport. Contact
- 349 (*Thousand Oaks*). 2023;6:25152564231208250. doi:10.1177/25152564231208250
- 350 29. Peikert K, Glaß H, Federti E, et al. Targeting Lyn Kinase in Chorea-Acanthocytosis: A
- 351 Translational Treatment Approach in a Rare Disease. J Pers Med. May 10
- 352 2021;11(5)doi:10.3390/jpm11050392